Clinical Efficacy of Calium Dobesilate Combined with Valsartan to Reduce Proteinuria of IgA Nephropathy / 中国药师

ABSTRACT

Objective:To observe the clinical efficacy of calcium dobesilate combined with valsartan in the treatment of IgA ne-phropathy. Methods:Totally 58 cases of IgA nephropathy were randomly divided into the treatment group and the control group. The control group enrolled 29 cases given valsartan 160 mg · d-1 . The treatment group included 29 cases treated with calcium dobesilate 500 mg·time-1 ,tid,and valsartan 160 mg·d-1 . After 6 months, the following indicators were observed, such as blood pressure,fi-brinogen,urea nitrogen,serum creatinine,blood uric acid,and 24-hour urinary ( Upro) . Results: After 6 months, UA and Upro of the two groups were significantly declined than those before the treatment(the control group P<0. 05,the treatment group P<0. 01). Upro of the treatment group was declined from (1. 48 ± 0. 84) g/24h to (0. 41 ± 0. 22) g/24h,and there was statistical significance com-pared with the control group (P<0.05). BUN, Scr and FIB were decreased significantly(P <0.05),while no significant change showed in those in the control group after the treatment. Conclusion:Calcium dobesilate combined valsartan can effectively reduce Up-ro and improve renal function in IgA nephropathy.